Whitepaper

When it comes to labeling compliance, historically, BioPharma could argue that they simply did not have the information available to identify potential compliance dissonance across their business units and affiliates: the “needle in a haystack” defense. Companies can leverage data and applying modern analytics to draw insights and navigate the risks across their entire labeling network. In addition, because of COVID disruptions in work and teams in different countries, compliance is given lesser priority by BioPharma. But health authorities will not agree with your constraints or priorities when getting into 2021.

To know in detail download your copy now.